Bio-Rad Laboratories, Inc.
FAIR PRICE VALUATION
Updated daily
Model: DCF 50% · Relative 30% · Consensus 20%
MARKET PRICE
$310.70
FAIR PRICE
$260.60
MARGIN
$50.10
P/E Ratio
N/A
Div. Yield
N/A
ROE
-10.0%
Average
Market Cap
$8B
Mid-cap
NOW AVAILABLE
Get notified when BIO-B's fair price changes
Push notifications when BIO-B's valuation shifts. Available on iOS and Android.
FPI RATING
Low debt levels, but volatile earnings pattern and below-average fundamental quality.
Analytical data, not an investment recommendation. Updated daily.
How we calculate this ↗MARGIN OF SAFETY
A 20% margin of safety below fair value — the conservative entry level for risk-aware investors.
SAFETY MARGIN
20%
Below fair value
ENTRY LEVEL
$208.48
Fair price × 0.80
DISTANCE
32.9%
Price to entry level
At the current price of $310.70, BIO-B trades 32.9% above the conservative entry level of $208.48. This entry level represents a 20% margin of safety below the calculated fair price of $260.60 — a buffer that accounts for estimation uncertainty in the valuation model.
Margin of safety is a risk management concept, not an investment recommendation. The 20% threshold follows Benjamin Graham's value investing framework. Fair price and entry levels are model-based estimates updated daily. Learn more about Margin of Safety ↗
VALUATION HISTORY
Loading chart data...
P/E RATIO HISTORY
Loading chart data...
METHODOLOGY
How we calculate BIO-B's fair price
Bio-Rad Laboratories, Inc.'s fair price of $260.60 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $310.70, BIO-B trades 16.1% above its calculated fair value.
DCF MODEL · 50%
Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting BIO-B's risk profile.
RELATIVE · 30%
Comparing BIO-B's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.
ANALYST · 20%
Aggregated analyst price targets for BIO-B, weighted by recency and analyst accuracy.
TRY IT YOURSELF
Want to test your own assumptions? Use our free calculators to estimate BIO-B's fair value with your own inputs.
LEARN MORE
POWERED BY BULIOS
Get full analysis, financials, and AI insights for BIO-B.
Explore on BuliosFAQ
What is the fair price of BIO-B?+
Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Bio-Rad Laboratories, Inc. is $260.60. At the current market price of $310.70, BIO-B trades 16.1% above its calculated fair value.
Is BIO-B overvalued or undervalued?+
Bio-Rad Laboratories, Inc. is currently overvalued based on our valuation model. The stock trades at $310.70, which is 16.1% above the fair price of $260.60.
What is the margin of safety for BIO-B?+
With a 20% margin of safety applied to the fair price of $260.60, the conservative entry level for BIO-B is $208.48. At the current market price of $310.70, the stock trades 32.9% above this entry level. Margin of safety is a risk management concept from Benjamin Graham's value investing framework, not an investment recommendation.
How often is BIO-B's fair price updated?+
We update fair price calculations for BIO-B daily after market close. The current fair price of $260.60 incorporates the latest market data and sector multiples.
What factors affect BIO-B's fair price calculation?+
BIO-B's fair price of $260.60 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight)., ROE of -10.0%.
Is BIO-B a good buy right now?+
At $310.70, BIO-B trades 16.1% above our fair value estimate of $260.60. The stock is currently overvalued. ROE stands at -10.0% (average). Fair Price Index provides valuation data — always do your own research before investing.
Does BIO-B pay dividends?+
BIO-B does not currently pay a dividend.
RELATED STOCKS
Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.